Fig. 2From: Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectivesComparison of the effect of sotagliflozin on HbA1c (a) and fasting plasma glucose (b) in various clinical trials on type 2 diabetic patientsBack to article page